Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology · Graft-versus-Host Disease

What Are the Early Signs of Acute and Chronic GVHD?

At a Glance

After a donor stem cell transplant, even a small new rash or slightly looser stool can be an early sign of GVHD. Acute GVHD often affects the skin, bowel, and liver, while chronic GVHD may affect the eyes, mouth, skin, lungs, muscles, and joints; report changes promptly.

In this answer

2 sections

01

Acute vs. Chronic GVHD: It’s About Patterns, Not Just the Calendar

02

When to Call Your Transplant Team

After an allogeneic stem cell transplant (using donor cells) for Blastic plasmacytoid dendritic cell neoplasm (BPDCN), typical recovery includes some fatigue and mild healing symptoms. However, Graft-versus-Host Disease (GVHD)—which happens when the donor’s immune cells attack your healthy tissues—requires prompt medical evaluation [1].

While it can be tempting to wait and see if a symptom worsens, you should report any new or changing symptom immediately. Even mild early signs, like a small rash or a slightly loose stool, should be evaluated by your transplant team [2][3]. Because GVHD can mimic common infections or drug reactions, your team needs to examine you and run tests to know for sure [4][5].

Important Safety Rules:

  • Never wait for symptoms to become “severe” before calling.
  • Do not stop or change your immunosuppression medicines without your doctor’s explicit instructions.
  • Avoid over-the-counter treatments (like anti-diarrheals, steroid creams, or medicated eye drops) unless approved by your transplant team.

Acute vs. Chronic GVHD: It’s About Patterns, Not Just the Calendar

Doctors classify GVHD as “acute” or “chronic” based on which organs are affected and the types of symptoms you have, rather than just the number of days since your transplant [6].

While acute GVHD usually starts within the first 100 days [7], it can happen later (known as late-onset acute GVHD) [8]. Similarly, chronic GVHD typically starts 4 to 6 months post-transplant, but can begin earlier or even years later [9]. It is also possible to have features of both at the same time.

Early Warning Signs of Acute GVHD

Acute GVHD most commonly affects the skin, digestive tract, and liver [6].

  • The Skin: Often the very first sign [10]. Watch for any new red, raised, or measles-like rash, which may start on the palms, soles, or shoulders [3]. Do not wait for it to spread before calling.
  • The Digestive Tract (Gastrointestinal): Report any increase in how often you go to the bathroom or the wateriness of your stool [2]. Acute GVHD can cause high volumes of watery diarrhea, nausea, vomiting, or abdominal pain [11].
  • The Liver: Importantly, early liver GVHD often has no visible symptoms at all and may happen without a rash [12]. It is usually first caught through routine blood tests checking your liver function [12]. Visible signs like yellowing of the skin or eyes (jaundice), dark urine, or pale stools are typically later signs.

Long-Term Signs of Chronic GVHD

Chronic GVHD is a broader syndrome that can affect almost any organ [13]. Key signs include:

  • Eyes and Mouth: Report any dry, gritty, or painful eyes, light sensitivity, or blurry vision [14]. In the mouth, look out for extreme dryness, white patches, sores, sensitivity to spicy or acidic foods, or difficulty opening your mouth fully [15].
  • Skin, Hair, and Nails: Unlike the early red rash of acute GVHD, chronic skin GVHD often causes the skin to feel tight, thick, itchy, or hardened (fibrotic) [16]. You might notice nail ridges, unexplained hair loss, or changes in the genital area [17].
  • Lungs: A new dry cough, wheezing, shortness of breath, or feeling winded faster than usual can indicate lung involvement [18].
  • Muscles and Joints: Unexplained joint stiffness, muscle weakness, or a reduced ability to move comfortably [19].

When to Call Your Transplant Team

Prompt reporting allows your team to evaluate and treat the underlying cause early; delayed diagnosis can postpone essential treatments [20].

Call your transplant clinic immediately (or their 24-hour after-hours number) if you have:

  • Any new rash, even if it is small [21].
  • An increase in stool frequency or looseness [2].
  • Any fever (check your center’s exact threshold, often 100.4°F or 38.0°C) [4].
  • New eye pain, grittiness, or vision changes [22].
  • New coughing, wheezing, or difficulty breathing [18].

Seek Emergency Care if you experience:

  • Severe shortness of breath.
  • Inability to keep any fluids down.
  • Severe abdominal pain or blood in your stool.
  • Fainting or confusion.

(If you cannot reach your transplant team, go to the nearest emergency room and tell them you are a recent allogeneic stem cell transplant recipient.)

Common questions in this guide

What are the first signs of acute GVHD?
Early acute GVHD often appears as a new red or raised rash, especially on the palms, soles, or shoulders. It can also cause more frequent or watery stools, nausea, vomiting, or abdominal pain. Liver involvement may have no visible symptoms and may first appear on routine blood tests.
What symptoms can chronic GVHD cause?
Chronic GVHD can cause dry, gritty, painful, light-sensitive, or blurry eyes and a dry mouth with sores or white patches. Other possible signs include tight or hardened itchy skin, hair or nail changes, a dry cough or breathlessness, and joint stiffness or muscle weakness.
Can GVHD start after the first 100 days following transplant?
Yes. Acute GVHD commonly begins within the first 100 days but can appear later, and chronic GVHD may start before or after its usual four-to-six-month timing, even years later. Doctors use the affected organs and symptom pattern, not the calendar alone, and some people have features of both.
When should I call my transplant team about possible GVHD?
Call your transplant clinic immediately about any new rash, increased stool frequency or looseness, fever, new eye symptoms, or new cough, wheezing, or breathing difficulty. Do not wait for symptoms to become severe, and do not change immunosuppression or use over-the-counter treatments without approval.
Which GVHD symptoms require emergency care?
Seek emergency care for severe shortness of breath, inability to keep fluids down, severe abdominal pain, blood in the stool, fainting, or confusion. If you cannot reach your transplant team, go to the nearest emergency room and explain that you recently had an allogeneic stem cell transplant.
Can liver GVHD occur without noticeable symptoms?
Yes. Early liver GVHD often causes no noticeable symptoms, so transplant teams monitor liver function with routine blood tests. Jaundice, dark urine, and pale stools can occur later, but you should not wait for them before reporting other changes.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What Is BPDCN's Long-Term Outlook and Survival Rate? What Do BPDCN Skin Lesions Look Like? Signs to Know Why Is a BPDCN Transplant Recommended While in Remission? How Rare Is BPDCN? Incidence and Who Usually Gets It What Are Tagraxofusp's Common Non-CLS Side Effects in BPDCN?
Show more
What Is the Pathophysiology of CLS During BPDCN Treatment? How Do CD123, CD4, and CD56 Support BPDCN Diagnosis? How Is Capillary Leak Syndrome Managed During Tagraxofusp? What Intensive Chemotherapy Regimens Are Used for BPDCN? Why Is BPDCN Frequently Misdiagnosed? Common Mimics What Do TET2, ASXL1, and ZRSR2 Mean in BPDCN NGS Results? What Is the Long-Term BPDCN Survivor Surveillance Schedule? How Does Tagraxofusp (Elzonris) Work Against BPDCN? What Do Plasmacytoid Dendritic Cells Do in Immunity? Which Slides and Reports Does a BPDCN Second Opinion Need? What Should I Ask My Oncologist About BPDCN Expertise? Why Might BPDCN Need Chemotherapy in the Spinal Fluid?

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific changes in my daily bowel movements should prompt an immediate call to the clinic versus an emergency room visit?
  2. 2.What is our clinic's specific fever threshold, and what is the 24-hour after-hours phone number I should use?
  3. 3.How frequently will my liver function be checked through blood tests, and what happens if the numbers change?
  4. 4.Are there any over-the-counter creams, antidiarrheals, or eye drops I should strictly avoid?
  5. 5.Which symptoms should I report immediately even if they occur outside the typical 100-day window?

References

References (22)
  1. 1

    Thoracic Air Leak Syndrome, Pulmonary Aspergillosis, and COVID-19 Pneumonia After Allogeneic Stem Cell Transplantation in a Child With Myelodysplastic Syndrome.

    Sever T, Kaya Z, Kirkiz S, et al.

    Journal of pediatric hematology/oncology 2022; (44(2)):e474-e478 doi:10.1097/MPH.0000000000002203.

    PMID: 34001788
  2. 2

    Mesenchymal Stem Cell Therapy Overcomes Steroid Resistance in Severe Gastrointestinal Acute Graft-Versus-Host Disease.

    Moritani K, Miyawaki R, Tokuda K, et al.

    Case reports in transplantation 2019; (2019()):7890673 doi:10.1155/2019/7890673.

    PMID: 31263624
  3. 3

    Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review.

    Villarreal CD, Alanis JC, Pérez JC, Candiani JO

    Anais brasileiros de dermatologia 2016; (91(3)):336-43.

    PMID: 27438202
  4. 4

    Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.

    Herling M, Schröder L, Awerkiew S, et al.

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2016; (74()):57-60.

    PMID: 26672492
  5. 5

    Topical therapy and skin care for transplant-associated atopic dermatitis in children and adolescents.

    Horino S, Yamaguchi Y, Miyabayashi H, et al.

    Pediatric transplantation 2024; (28(1)):e14653 doi:10.1111/petr.14653.

    PMID: 37990976
  6. 6

    Acute graft-versus-host disease.

    Malard F, Holler E, Sandmaier BM, et al.

    Nature reviews. Disease primers 2023; (9(1)):27 doi:10.1038/s41572-023-00438-1.

    PMID: 37291149
  7. 7

    The role of fecal microbiota transplantation in the treatment of acute graft-versus-host disease.

    Guo Z, He M, Shao L, et al.

    Journal of cancer research and therapeutics 2024; (20(7)):1964-1973 doi:10.4103/jcrt.jcrt_33_24.

    PMID: 39792405
  8. 8

    Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.

    Akahoshi Y, Spyrou N, Hogan WJ, et al.

    Blood advances 2023; (7(16)):4479-4491 doi:10.1182/bloodadvances.2023009885.

    PMID: 37315175
  9. 9

    Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease.

    Gunes G, Demiroglu H, Goker H, et al.

    Case reports in hematology 2015; (2015()):692175 doi:10.1155/2015/692175.

    PMID: 26613052
  10. 10

    Review of Graft-Versus-Host Disease.

    Ramachandran V, Kolli SS, Strowd LC

    Dermatologic clinics 2019; (37(4)):569-582 doi:10.1016/j.det.2019.05.014.

    PMID: 31466596
  11. 11

    Diagnosing Acute Graft-Versus-Host Disease in Children Undergoing Hematopoietic Stem Cell Transplantation-Comparison of the Modified Glucksberg Criteria Versus the MAGIC Criteria.

    Weischendorff S, Kamari-Kany N, Kielsen K, et al.

    Pediatric blood & cancer 2025; (72(3)):e31502 doi:10.1002/pbc.31502.

    PMID: 39776234
  12. 12

    Successful Management of Severe Hepatic Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β-Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation.

    Alhiraki H, Fares AA, Kheder M

    Clinical case reports 2026; (14(10)):e73623 doi:10.1002/ccr3.73623.

    PMID: 42801017
  13. 13

    Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

    Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al.

    Blood 2019; (134(3)):304-316 doi:10.1182/blood.2019000216.

    PMID: 31043425
  14. 14

    Ocular graft-versus-host disease (oGVHD): From A to Z.

    Soleimani M, Mahdavi Sharif P, Cheraqpour K, et al.

    Survey of ophthalmology 2023; (68(4)):697-712 doi:10.1016/j.survophthal.2023.02.006.

    PMID: 36870423
  15. 15

    Acute calcareous corneal degeneration in a patient with chronic graft-versus-host disease.

    Ruiz MGS, Pérez LA, Picazo CC, et al.

    Romanian journal of ophthalmology 2024; (68(1)):53-56 doi:10.22336/rjo.2024.10.

    PMID: 38617729
  16. 16

    Adult Cutaneous Chronic Graft-Versus-Host Disease: An In-Depth Review.

    Atique A, Kanou M, Netchiporouk E, et al.

    Journal of cutaneous medicine and surgery 2026; 12034754261455768 doi:10.1177/12034754261455768.

    PMID: 42400422
  17. 17

    Cutaneous manifestations of acute and chronic graft-versus-host disease.

    Cho A, Paulitschke V, Just U, Knobler R

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; (155(1)):76-87 doi:10.23736/S0392-0488.19.06535-0.

    PMID: 32100975
  18. 18

    Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.

    Shahzad M, Chaudhary SG, Basit A, et al.

    Transplant immunology 2022; (70()):101520 doi:10.1016/j.trim.2021.101520.

    PMID: 34952168
  19. 19

    Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature.

    Kvinge AD, Kvammen T, Miletic H, et al.

    Current oncology (Toronto, Ont.) 2022; (29(11)):8415-8430 doi:10.3390/curroncol29110663.

    PMID: 36354723
  20. 20

    Extensive acute cutaneous graft versus host disease: A rare case report of survival.

    Pudasaini P, Paudel S, Sagar GC, et al.

    Clinical case reports 2023; (11(6)):e7545 doi:10.1002/ccr3.7545.

    PMID: 37323259
  21. 21

    Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease.

    Mahabal G, George L, Bindra M, George B

    Indian dermatology online journal 2016; (7(6)):509-511 doi:10.4103/2229-5178.193921.

    PMID: 27990387
  22. 22

    Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

    Curtis LM, Datiles MB, Steinberg SM, et al.

    Haematologica 2015; (100(9)):1228-36 doi:10.3324/haematol.2015.124131.

    PMID: 26088932

This page is for informational purposes only and does not constitute medical advice. After an allogeneic transplant, contact your transplant team about new symptoms and follow its instructions for medicines and emergency care.